Global Vaccine and Immunization Research Forum (GVIRF)

Angela Hwang

The Global Vaccine and Immunization Research Forum (GVIRF) is the central discussion platform of all research and innovation aspects related to the Immunization Agenda 2030 (IA2030). GVIRF gathers together leading experts from public health, academia, government, civil society and private sector and serves as a forum to:

  • Track progress and discuss obstacles related to priority vaccine research and development (R&D);
  • Identify gaps, opportunities and actions for the R&D community in the areas of vaccines and immunization;
  • Create opportunities for networking and collaboration among the vaccine R&D and immunization communities; and
  • Review progress made towards the IA2030 R&D strategic objectives and goals.

As endorsed by the IA2030 Leadership Council and theWorld Health Organization Strategic Advisory Group of Experts, research and innovation reporting for the IA2030 is conducted every two years by the GVIRF, with emphasis on:

  • Expanding capabilities of engagement with end-users,
  • Enabling development of new vaccines,
  • Accelerating development, licensing and update of vaccines, and
  • Improving programme efficiencies and increasing coverage.

GVIRF is co-hosted by the World Health Organization, the National Institute of Allergy and Infectious Diseases, and the Bill & Melinda Gates Foundation.

The last meeting was held in March 2023. Between GVIRF meetings, GVIRF Webinars are exploring late-breaking developments in specific topics, such as mRNA vaccine technologies and malaria vaccines. 

Past and upcoming GVIRF meeting and webinar announcements, agendas, videos, and presentations are available below. For more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Next event (English)

This collection contains information about the next GVIRF meeting or webinar.

GVIRF Webinars (English)

This collection contains materials from the ongoing series of GVIRF Webinars.

2021-10-14 mRNA Vaccine Technologies for Global Health - AGENDAGVIRF Secretariat2021PresentationEnglish
2021-10-14 mRNA Vaccine Technologies for Global Health - PRESENTATIONSGVIRF Secretariat2021PresentationEnglish
2021-10-14 mRNA Vaccine Technologies for Global Health - VIDEOGVIRF Secretariat2022WebinarEnglish
2022-03-03 Malaria Vaccine R&D and Immunization Lessons Learned and Considerations for Global Health Impact - VIDEOGVIRF Secretariat2022WebinarEnglish
2022-03-03 Malaria Vaccine R&D and Immunization: Lessons Learned and Considerations for Global Health Impact - AGENDAGVIRF Secretariat2022PresentationEnglish
2022-06-23 AMR: Las vacunas como herramientas para prevenir la RAM - VIDEOGVIRF Secretariat2022WebinarSpanish
2022-06-23 AMR: Les vaccins comme outils de prévention de la RAM - VIDEOGVIRF Secretariat2022WebinarFrench
2022-06-23 AMR: Vaccines as Tools to Prevent Antimicrobial Resistance - VIDEOGVIRF Secretariat2022WebinarEnglish
2022-06-23 AMR: Vaccines as Tools to Prevent Antimicrobial Resistance: Advances, challenges, and future development - AGENDAGVIRF Secretariat2022PresentationEnglish
2022-06-23 Vaccines as Tools to Prevent Antimicrobial Resistance: Advances, challenges, and future development - WEBINAR ANNOUNCEMENTGVIRF Secretariat2022PresentationEnglish
2022-10-12 Correlates of Protection - VIDEOGVIRF Secretariat2022WebinarEnglish
2023-09-13 Webinar: Vaccine Adjuvants for Global Health - Final AGENDAGVIRF Secretariat2023WebinarEnglish
2023-09-13 Webinar: Vaccine Adjuvants for Global Health - Session I Global Demand for Vaccine AdjuvantsGVIRF Secretariat2023PresentationEnglish
2023-09-13 Webinar: Vaccine Adjuvants for Global Health - Session II Selection of Adjuvant and Formulation for Vaccine R&D: rational or empirical?GVIRF Secretariat2023PresentationEnglish
2023-09-13 Webinar: Vaccine Adjuvants for Global Health - Session III Access to AdjuvantsGVIRF Secretariat2023PresentationEnglish
2023-09-13 Webinar: Vaccine Adjuvants for Global Health - VIDEOGVIRF Secretariat2023WebinarEnglish
GVIRF Webinar: New TB Vaccines for Adults & Adolescents: Progress, Prospects and Perspectives; February 22, 2024 - FINAL AGENDAGVIRF Secretariat2024WebinarEnglish
GVIRF Webinar: New TB Vaccines for Adults and Adolescents, Progress, Prospects, and Perspectives, February 22, 2024 - ANNOUNCEMENTGVIRF SecretariatWebinarEnglish

GVIRF 2023 (English)

This collection contains materials from GVIRF 2023.

Agenda - GVIRF 2023 - PRINTABLEGVIRF Secretariat2023PresentationEnglish
GVIRF 2023 Poster AbstractsGVIRF Secretariat2023Poster/infographicEnglish
GVIRF 2023 Welcome and Opening RemarksLee Hall2023WebinarEnglish
Keynote 1 - Vaccines in the Post-COVID Era: Can Policy and Practice Keep up with ScienceBarney Graham2023WebinarEnglish
Keynote 2 - Future Pandemic R&D Preparedness in Korea and Translating Pandemic R&D Learnings into the Broader Global Health AgendaHeechang Jang, NIH Korea; Jerome Kim, IVI2023WebinarEnglish
KN1 Vaccines in the post-COVID era: Can policy and practice keep up with science?Barney Graham2023PresentationEnglish
KN2-1 Future Pandemic R&D Preparedness in KoreaHee-Chang Jang2023PresentationEnglish
KN2-2 Translating pandemic R&D learnings into the broader global health agendaJerome Kim2023PresentationEnglish
P1 From GVAP to IA2030: roles of vaccine R&D to enable successLee Hall2023WebinarEnglish
P1-1 Overview of GVAP and IA2030Lee Hall2023PresentationEnglish
P1-2 Lessons Learned from the Global Vaccine Action PlanNoni MacDonald2023PresentationEnglish
P1-3 Looking Ahead – Themes that will influence the R&D agendaHelen Matzger2023PresentationEnglish
P1-4 IA2030 Strategic Priority 7: Research & Innovation. Overview and goalsKwaku Poku Asante2023PresentationEnglish
P1-5 Partnering with regions and countries to identify priority pathogens for vaccinesBirgitte Giersing2023PresentationEnglish
P2 - Lessons from COVID-19 vaccines and future pandemic preparednessCharlie Weller2023WebinarEnglish
P2-2 Research & innovation: Outbreaks preparedness & responseAna Maria Henao Restrepo2023PresentationEnglish
P2-3 CEPI's Lessons Learnt from COVID-19 pandemic response and the 100 day mission for pandemic preparednessMelanie Saville2023PresentationEnglish
P2-4 Regulatory Perspective: BrazilGustavo SantosPresentationEnglish
P2-5 Lessons learned from an industry R&D perspectiveTonya Villafana2023PresentationEnglish
P3 - Current status of R&D for HIV, TB, Malaria, and Universal Influenza vaccines (and reports from Workshops 1-3)Annie Mo, Jerome Kim2023WebinarEnglish
P3-1 Introduction: Current status of vaccine R&D for HIV, Tb, Malaria, and Universal fluAnnie Mo2023PresentationEnglish
P3-3 Tuberculosis Vaccine R&DMark Hatherill2023PresentationEnglish
P3-4 HIV Vaccine UpdateShan Lu2023PresentationEnglish
P3-5 Current Status of Universal Influenza Vaccine Research and DevelopmentPunnee Pitisuttithum2023PresentationEnglish
P4-1 The Full Value of Vaccines Assessment (FVVA) conceptMark Jit2023PresentationEnglish
P4-2 Using the FVVA framework to estimate the potential health and economic impacts of novel TB vaccines in low- and middle-income countriesRichard White2023PresentationEnglish
P4-3 The Full Vacccine Accessment for Group A Streptococcus VaccinesDavid Bloom2023PresentationEnglish
P4-4 A Pathway to Impact: Exploring the potential of measles rubella microarray patches to reach zero dose children and improve measles vaccine coverage through an initial Full Value Vaccine AssessmentJean-Pierre Amorij2023PresentationEnglish
P5 - Innovating to find and reach Zero-Dose ChildrenSamir Sodha2023WebinarEnglish
P5-1 Introduction to Zero-DoseSamir Sodha2023PresentationEnglish
P5-2 Mapping the distribution of zero-dose children and their characteristics in low- and middle-income countriesC. Edson Utazi2023PresentationEnglish
P5-3 Using mHealth Interventions to Improve Vaccination CoverageAbdul Momin Kazi2023PresentationEnglish
P5-4 Strengthening Routine Immunization: Use of Reaching Every District - Quality Improvement (RED-QI) approachMelkamu Ayalew2023PresentationEnglish
P6 - Vaccine technologies for equityPhilippe-Alexandre Gilbert2023WebinarEnglish
P6-2 The Vaccine Innovation Prioritisation Strategy (VIPS): driving innovations to improve vaccine delivery in low- and middle-income countriesJean-Pierre Amorij2023PresentationEnglish
P6-3 A low footprint vaccine manufacturing platform for in-country, for-country productionMathias Garny2023PresentationEnglish
P6-4 Single Injection VaccinesAna Jaklenec2023PresentationEnglish
P6-5 EuBiologics’s Vaccine Technologies for EquityRachel Park2023PresentationEnglish
P7 Optimizing vaccine regimensAndrew Pollard, Kristen Earle2023WebinarEnglish
P7-1 GVIRF Plenary 7: Optimizing vaccine regimensKristen Earle2023PresentationEnglish
P7-2 Optimizing immunization schedulesNaor Bar-Zeev2023PresentationEnglish
P7-3 Impact on immunogenicity: Dose, Schedule and PlatformAndrew Pollard2023PresentationEnglish
P7-4 Optimizing vaccine regimens – HPV VaccinesDeborah Watson-Jones2023PresentationEnglish
P7-5 Timing of South Africa's PCV and  Measles infant doses: considerations on the adoption of a vaccine scheduleRudzani Muloiwa2023PresentationEnglish
P8 - Reflections and closing remarks: Progress and the path forwardNoni MacDonald, Dalhousie U.2023WebinarEnglish
W1 - Immunological and Vaccine Considerations for Special Populations: women of reproductive age and pregnancy, people living with HIV, and older adultsCarolyn Deal, Ruth Karron2023WebinarEnglish
W1-2 Vaccines for special populations: Immunological considerationsArnaud Didierlaurent2023PresentationEnglish
W1-3 Group B Streptococcus Vaccination in Pregnant WomenAnna Seale2023PresentationEnglish
W1-4 TB Vaccine Roadmap for People Living with HIVMindy Miner2023PresentationEnglish
W1-5 COVID 19 vaccine effectiveness in the elderly populationTarun Saluja2023PresentationEnglish
W2 - Novel vaccine platformsMax Silverman, Sue Ann Clemens2023WebinarEnglish
W2-3 mRNA and adjuvants friends…or foes ?Nathalie Garcon2023PresentationEnglish
W2-4 Nanoparticle Vaccines: A success story for viral vaccine developmentHarry Kleanthous2023PresentationEnglish
W2-5 New Developments in Viral Vector VaccinesJerry Sadoff2023PresentationEnglish
W3 - Regional manufacturingMartin Friede2023WebinarEnglish
W3-2 An African Mission - Establish and SustainPatrick Tippoo2023PresentationEnglish
W3-3 Biological E. LimitedMahima Datla2023PresentationEnglish
W3-4 Gavi’s Strategy to Support Regional ManufacturingMarta Tufet2023PresentationEnglish
W3-5 The case for globally distributed vaccine manufacturing - CEPI perspectiveMelanie Saville2023PresentationEnglish
W4 - Mucosal immunity and vaccinesMelanie Saville2023WebinarEnglish
W4-1 Mucosal Immunity: Opening RemarksMelanie Saville2023PresentationEnglish
W4-2 Mucosal Immunity: What’s special about it and can vaccines induce it?Peter Openshaw2023PresentationEnglish
W4-3 A Mucosally-delivered Newcastle Disease Virus-vectored Booster Vaccine to Prevent SARS-CoV-2 Breakthrough Infection and TransmissionMichael Egan2023PresentationEnglish
W4-4 Adenovirus Vector Based Covid-19 Inhalation VaccineChunlin Xin2023PresentationEnglish
W4-5 mRNA-lipid nanoparticle vaccines for intranasal deliveryDarin Edwards2023PresentationEnglish
W4-6 A translational Research Institute focused on vaccines and airway immunityPeter Andersen2023PresentationEnglish
W5 - Vaccine development strategies at the intersection of market model, value drivers, and access policyJessica Martinez, Raman Rao2023WebinarEnglish
W5-4 The Next Frontier in Defining Value: Health Economics in LMICsAlice Chen2023PresentationEnglish
W5-5 Developing vaccines as global public good: RIGHT foundation’s approachHani Kim2023PresentationEnglish
W6-1 What is implementation research and why is it important?Alexander Rowe2023PresentationEnglish
W6-3 Implementation research needs on vaccine delivery according to epidemiological contextHalidou Tinto2023PresentationEnglish
W6-4 Reaching adolescent girls with the HPV vaccineCathy Ndiaye2023PresentationEnglish
W6-5 Protecting young infants through immunopreventionJessica Fleming2023PresentationEnglish
W7 - New vaccines on the horizonAlejandro Cravioto, Shahida Baqar2023WebinarEnglish
W7-2 Dengue VaccinesAnnelies Wilder-Smith2023PresentationEnglish
W7-3 2023: the year of RSVRuth Karron2023PresentationEnglish
W7-4 Enteric Disease: Shigella and ETEC Vaccine DevelopmentMichelo Simuyandi2023PresentationEnglish
W8 - Select poster highlightsPeter Dull, Sinead Delany-Moretlwe2023WebinarEnglish
W8-1 Workshop 8: Select Poster HighlightsPeter Dull2023PresentationEnglish
W8-2 Changing the HPV Landscape with Indigenous Vaccine: CERVAVACHitt Sharma2023PresentationEnglish
W8-3 High prevalence of rotavirus infection among under five children despite a high rotavirus vaccination coverage in EthiopiaDebasu Damtie2023PresentationEnglish
W8-4 Innovative DDS "DegradaBALL" for mRNA vaccine against next pandemics: "100 days mission"Dal-Hee Min2023PresentationEnglish
W8-5 Cross-neutralization of Influenza A by SARS-CoV-2 antibodiesMohammad Mamun Alam2023PresentationEnglish
W8-6 Nucleoprotein Antigen Adjuvanted with Liposomal Cholesterol-linked TLR7/8 Agonist Showed Protective Immunity in Influenza Mouse ModelChul Kim2023PresentationEnglish
W8-7 RV 460 Study: Comparative Adjuvant Study or HIV Env-C DNA and Protein Vaccines in KenyaJosphat Kiprop Kosgei2023PresentationEnglish
W8-8 The landscape of infectious disease exposure over the past two decades in the Kenyan coastTimothy Chege2023PresentationEnglish
W8-9 Polyvalent strategy to the development of broadly protective vaccines against COVID-19 subvariantsChang-Yuil Kang2023PresentationEnglish
W9-1 Understanding and addressing behavioural and social driversLisa Menning2023PresentationEnglish
W9-2 Vaccine uptake and equity: How to understand and address low uptakeJulie Leask2023PresentationEnglish
W9-3 Applying Social Science & Behavioural Design in Development and Humanitarian settings: Middle East & North AfricaAmaya Gillespie2023PresentationEnglish
W9-4 Use of Social data to inform programmatic action for COVID-19 vaccine uptake in NigeriaHadley Ikwe2023PresentationEnglish
Welcome & Opening remarksLee Hall2023PresentationEnglish

GVIRF 2021 (English)

This collection contains materials from GVIRF 2021.

*Meeting Summary: Global Vaccine and Immunization Research Forum, 2021Andrew FordJournal articleEnglish
Agenda - GVIRF 2021GVIRF Secretariat2021PresentationEnglish
Introduction to GVIRFB. Fenton Hall2021WebinarEnglish
KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experienceAnthony Fauci2021WebinarEnglish
KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experienceAnthony Fauci2021PresentationEnglish
KN2 The Lessons of COVID-19 for Vaccine DevelopmentBill & Melinda Gates Foundation2021WebinarEnglish
KN2.2 Innovating from Research to Impact at Scale: the role of the Gavi AllianceAnuradha Gupta2021WebinarEnglish
KN3 Research for EquitySoumya Swaminathan2021PresentationEnglish
KN3 Research for Equity - VIDEOSoumya Swaminathan2021WebinarEnglish
P1 Epidemic and Pandemic Preparedness and ResponseGeorge F. Gao, Helen ReesWebinarEnglish
P1.1 Research during outbreak response: from Ebola to the COVID-19 pandemicAna Maria Henao Restrepo2021PresentationEnglish
P1.2 Rapid Response Platforms for COVID-19 VaccineMelanie Saville2021PresentationEnglish
P1.3 Rapid (and precise) COVID-19 Vaccine Development Enabled by Prototype Pathogen PreparednessBarney S. Graham2021PresentationEnglish
P2 HIV, TB & Malaria Vaccine UpdateNorman Baylor, Lucky Slamet2021WebinarEnglish
P2.1 Current status and future prospects for human immunodeficiency virus (HIV) vaccinesLinda-Gail Bekker, University of Cape Town2021PresentationEnglish
P2.2 Update on progress in tuberculosis vaccine developmentAnn Ginsberg2021PresentationEnglish
P3 Shaping the Future: Equitable Access for AllDaniel Feikin, Robin NandyWebinarEnglish
P3.1 The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030Katherine L. O'Brien2021PresentationEnglish
P3.2 Impact of COVID-19 on coverage and equitySamir Sodha2021PresentationEnglish
W1 Innovations in Vaccine ManufacturingAntu Dey, Rajat GoyalWebinarEnglish
W1.2 Vaccine Manufacturing at Lab Scale: A paradigm shift to more affordable vaccinesAhd Hamidi2021Case studyEnglish
W1.3 Not enough to go around: vaccine manufacturing for the COVID-19 pandemicCasey SelwynPresentationEnglish
W2 Emerging PlatformsLynda Stuart, Kanta Subbarao, Florian Krammer, Nathalie Garcon, Sarah Gilbert, Christian Mandl2021WebinarEnglish
W2.1 Nucleic acid vaccines: Is it all done?Christian MandlPresentationEnglish
W2.2 Viral vectored vaccine platform technologiesSarah Gilbert, University of Oxford2021PresentationEnglish
W2.3 AdjuvantsNathalie Garcon2021PresentationEnglish
W2.4 Universal Influenza VaccinesKanta Subbarao2021PresentationEnglish
W3 Innovation in VaccinationBernhards Ogutu, David DurrheimWebinarEnglish
W3.2 Transformative Concepts for Mass Vaccination and Pandemic ResponseMatthew Downham, CEPI2021PresentationEnglish
W3.3 Considerations for mass deployment of innovative vaccines in low- and middle-income country immunization programsFred WerePresentationEnglish
W4 Controlled Human Infection Models for Vaccine Research and DevelopmentAnnie Mo, Gagandeep KangWebinarEnglish
W4.1 Controlled human malaria infection — tool for accelerating vaccine developmentMelissa Kapulu, KEMRI-Wellcome Trust Research Programme2021PresentationEnglish
W4.2 Typhoid controlled human infection modelAndrew Pollard2021PresentationEnglish
W5 New and Improved Vaccines on the HorizonKathleen NeuzilWebinarEnglish
W5.1 Salmonella typhi vaccines, development and deploymentSushant Sahastrabuddhe, International Vaccine Institute2021PresentationEnglish
W5.2 Schistosomiasis vaccines, development and role in eliminationRobert Bergquist, Geospatial Health2021PresentationEnglish
W5.3 Single-dose HPV VaccinationAimee R. Kreimer2021PresentationEnglish
W5.4 Improved vaccines: Novel oral polio vaccine (OPV)Ananda S. Bandyopadhyay2021PresentationEnglish
W6 Vaccine Development to AccessAlejandro Cravioto, Birgitte Giersing, David Kaslow, Deepali Pate, Ian Hudson, Joshua Chu, Narendra Arora, Rino Rappuoli, Sai Prasad2021WebinarEnglish
W6.1 Vaccine Development to Access: Opportunities, risks and potential valleys of deathDavid Kaslow2021PresentationEnglish
W6.2 Vaccine development to access: Is there a role for earlier policy consideration?Rino Rappuoli, GSK Vaccines2021PresentationEnglish
W6.3 Building the concept of WHO Vaccine Preferred Policy ProfilesBirgitte Giersing2021PresentationEnglish
W7.1 Protection of newborn infants through vaccinationTobias KollmannPresentationEnglish
W8 Prioritization for Vaccine R&DPeter Hotez, Jerome Kim, B. T. Slingsby2021WebinarEnglish
W8.1 Decision-making and prioritization of vaccines to address public health needs in LMICsBill HausdorffPresentationEnglish
W8.2 Prioritization of Vaccines for Global HealthJerome Kim2021PresentationEnglish
W8.3 The State of Play: Industry vaccine trends from the Access to Medicine IndexMargo Warren, Access to Medicine Foundation2021PresentationEnglish
W9 Building and Sustaining UptakeLisa Menning2021Case studyEnglish
W9.1 Building and Sustaining Uptake: Summary of the latest evidence and open research questionsJulie Leask2021PresentationEnglish
W9.2 Evidence and Lessons Learned on Social Sciences Analytics around VaccinationSimone Carter2021Case studyEnglish
W9.3 Building and Sustaining Uptake: Case study the PhilippinesAnna Ong-Lim2021Case studyEnglish

GVIRF 2018 (English)

This collection contains materials from GVIRF 2018.

P3.2 Developing Country Vaccine Manufacturers - Access to ImmunizationLakshminarayana Neti2018PresentationEnglish
*Meeting report: Global vaccine and immunization research forum, 2018Angela Hwang, B. Fenton Hall, Martin Friede, Peter Dull2019Journal articleEnglish
Agenda - GVIRF 2018GVIRF Secretariat2018PresentationEnglish
Introduction to GVIRFB. Fenton Hall2018PresentationEnglish
KN1 Beyond effectiveness: research on vaccines seen as a continuumAlejandro Cravioto2018PresentationEnglish
KN2 National and regional capacity for biotechnology research; Indian experienceMaharaj Kishan Bhan2018PresentationEnglish
P1 Progress Towards and Commonalities in Vaccine Development Against HIV, TB, and MalariaMary Marovich2018ReportEnglish
P1.1 Advanced Clinical Development of HIV VaccinesK. T. Mngadi2018PresentationEnglish
P1.2 Commonalities across vaccine development effortsPunnee Pitisuttithum2018PresentationEnglish
P1.3 Progress towards vaccines against TBGerald Voss2018PresentationEnglish
P1.4 Global Pipeline for Malaria Vaccines: Progress and Challenges to accelerate vaccine developmentFred Binka2018PresentationEnglish
P1.5 Gaps in Malaria VaccinesJ. Kevin Baird2018PresentationEnglish
P2 Innovating for EquityNarendra Arora2018ReportEnglish
P2.1 Intensified Mission Indradhanush: Addressing Equity in ImmunizationPradeep Haldar2018PresentationEnglish
P2.2 Use of Multiple Measures for Immunization Management in Migratory PopulationLin Luan2018PresentationEnglish
P2.4 Social Media Initiative in Ukraine: Analysis of Conversations on Polio, Vaccination and Routine ImmunizationAnna Postovoitova2018PresentationEnglish
P2.5 Universal Health Coverage: a people-centred approachBirgitte Giersing2018PresentationEnglish
P2.6 Strengthening Vaccination Programs among the Urban Poor: Closing the Equity GapFolake Olayinka2018PresentationEnglish
P3 Growing Developing Country Vaccine ManufactureA. A. Adeyemo2018ReportEnglish
P3.1 Vaccine Production in Developing Countries: an Economic EvaluationSyarifah Liza Munira2018PresentationEnglish
P3.3 Vaccine Manufacturing in Developing Countries: Perspectives on Approaches to Take, and Factors to Consider, towards Sustainable Manufacturing CapacityMartin Nicholson2018PresentationEnglish
P3.4 Addressing Patent Barriers to Vaccine Development & AccessKate Elder2018PresentationEnglish
P4 Regulatory Capacity, Challenges, and ConvergencesNorman W. Baylor2018ReportEnglish
P4.1 Alternative Regulatory Pathways: Opportunities and ChallengesNorman W. Baylor2018PresentationEnglish
P4.2 Benefits and Challenges: How regulators can reduce time and efforts in the case of public health emergencies?Yeowon Sohn2018PresentationEnglish
P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from ThailandAkanid Wapeewuttikorn2018PresentationEnglish
P5 Evidence for Decision MakingDavid Kaslow, Robert BreimanReportEnglish
P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseasesDavid Kaslow2018PresentationEnglish
P5.2 Evidence for Decision MakingYot Teerawattananon2018PresentationEnglish
P6 Polio Endgame: Needs and OpportunitiesRoland SutterReportEnglish
P6.1 Intro Polio Endgame: Needs and OpportunitiesRoland Sutter2018PresentationEnglish
P6.2 Global tOPV withdrawal: "The Switch" experienceAlejandro Ramirez Gonzalez2018PresentationEnglish
P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2?Ondrej Mach2018PresentationEnglish
P6.4 Polio Vaccines - R&D UpdatesPeter Dull2018PresentationEnglish
P6.5 Research for polio policy making: Lessons learnedRoland Sutter2018PresentationEnglish
P7 Discussion with Thought LeadersPeter Dull2018ReportEnglish
W1 Emerging Vaccine Strategies & TechnologiesPaula Bryant2018ReportEnglish
W1.1 MIMIC: an in vitro model of human immunityDon Drake2018PresentationEnglish
W1.2 New Vaccine Strategies using cytomegalovirusKlaus Früh2018PresentationEnglish
W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) VaccinesJohan Neyts, Kai Dallmeier2018PresentationEnglish
W2 R&D Update: Enteric VaccinesGagandeep Kang, Jean-Pierre Amorij2018ReportEnglish
W2.1 An update on rotavirus vaccinesGagandeep Kang2018PresentationEnglish
W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccinesCal MacLennan2018PresentationEnglish
W2.3 Controlled Human Infection Models and Enteric Vaccine DevelopmentBeth Kirkpatrick2018PresentationEnglish
W3 Pneumococcal Vaccines: Lessons Learned and the Road AheadHani Kim2018ReportEnglish
W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and ImpactKatherine L. O'Brien2018PresentationEnglish
W3.2 Rollout of Pneumococcal Conjugate Vaccine in IndiaNarendra K Arora, Pradeep Haldar2018PresentationEnglish
W3.3 The Future of Pneumococcal Conjugate VaccinesKeith Klugman2018PresentationEnglish
W4 Immunological Principles of Vaccines and VaccinationAnnie Mo, Bernhards Ogutu2018ReportEnglish
W4.1 New Approaches to Understanding Human ImmunityAnnie Mo2018PresentationEnglish
W4.2 Immunological Challenges in vaccination and vaccine developmentAndrew Pollard2018PresentationEnglish
W4.3 New technologies for studying human immunityLisa Wagar2018PresentationEnglish
W4.4 RTS,S Malaria Vaccine: Toward an understanding of the immunologic basis of protectionChristian Ockenhouse2018PresentationEnglish
W5 Epidemic and Pandemic PreparednessMartin Friede2018ReportEnglish
W5.1 WHO R&D Blueprint Update: progress and PlansMartin Friede2018PresentationEnglish
W5.2 Influenza Pandemic Risk and PreparednessJohn S. Tam2018PresentationEnglish
W5.3 Epidemic Preparedness: National Security for ThailandPunee Pitisuttithum2020PresentationEnglish
W5.4 Universal Influenza Vaccines and Their Role in PreparednessJennifer Gordon2018PresentationEnglish
W6 Reaching Adolescents and Pregnant WomenOdile Leroy2018ReportEnglish
W6.1 Reaching Adolescents & Pregnant Women (Introduction)Odile Leroy2018PresentationEnglish
W6.2 Adolescent Immunization in Developing Countries: Obstacles and OpportunitiesHartono Gunardi2018PresentationEnglish
W6.3 Maternal and adolescents immunization - a global challengeRaymond Hutubessy2018PresentationEnglish
W7 New Vaccine Pipeline: Lessons Learned and Accelerating ProgressJean-Pierre Amorij2018ReportEnglish
W7.1 Global Vaccine Pipeline and Value PropositionDavid Kaslow2018PresentationEnglish
W7.2 Update on RSV Vaccine and mAb developmentRuth Karron2018PresentationEnglish
W7.3 A Hepatitis C Virus Vaccine UpdateAndrea Cox2018PresentationEnglish
W7.4 Human Hookworm Vaccine Initiative: a Public Health value proposition leading to societal impact and positive financial returnsMaria Elena Bottazzi2018PresentationEnglish
W7.5 Target Value PropositionJean Lang2018PresentationEnglish
W8 Vaccines and Antimicrobial Resistance (AMR)A. A. Adeyemo2018ReportEnglish
W8.1 Antimicrobial Resistance and VaccinesDennis Dixon2018PresentationEnglish
W8.2 Vaccination against bacterial diseases in farmed Atlantic salmon: experience and global applicabilityEdgar Brun2018PresentationEnglish
W8.3 The Principle and Process of Autogenous VaccineSuphot Wattanaphansak2018PresentationEnglish
W9 Antibody-Mediated PreventionNina Russell2018ReportEnglish
W9.1 Pipeline of HIV monoclonal antibodies for prevention of HIVBarney Graham2018PresentationEnglish
W9.2 Monoclonal antibodies for rabies post-exposure prophylaxisErin Sparrow2018PresentationEnglish
W9.3 Monoclonal Antibodies for Influenza Prevention, Therapy, or Vaccine Antigen DesignBruce Innis2018PresentationEnglish
W9.4 Antibody Engineering: Optimization of Antibodies for CommercializationStephen Hadley2018PresentationEnglish

GVIRF 2016 (English) 

This collection contains materials from GVIRF 2016.

*Meeting report: Global vaccine and immunization research forumAndrew Ford, Angela Hwang, B. Fenton Hall, Joachim Hombach, Nancy Touchette2018Journal articleEnglish
Context and Purpose of GVIRFThomas Cherian2016ReportEnglish
KN1 Opening Session and Dr Margaret Chan KeynoteGVIRF Secretariat2016ReportEnglish
KN3 Vaccine Manufacturing in Africa: Self-sufficiency, a need? Or a dream?William Ampofo2016PresentationEnglish
P1.1a RSA & HIV vaccine efficacy studiesGlenda Gray2016PresentationEnglish
P1.1b HIV Vaccines: Marry HIV efficacy studies to science, but take shots on goalNelson Michael2016PresentationEnglish
P1.2a TB Vaccine Research and Development: Progress, Strategies and ControversiesLewis Schrager2016PresentationEnglish
P1.3a Malaria VaccinesEusebio Macete2016PresentationEnglish
P1.3b Vaccines for Malaria - Updates on ProgressMahamadou Thera2016PresentationEnglish
P2 The role of moderate efficacy vaccines in integrated disease control strategiesKatherine L. O'Brien2016ReportEnglish
P2.1 The role of moderate efficacy vaccines in integrated disease control strategies: IntroductionKathleen Neuzil2016PresentationEnglish
P2.2 Lessons from Rotavirus and Pneumococcal Conjugate VaccinesKatherine L. O'Brien2016PresentationEnglish
P2.3 Moderate efficacy malaria vaccines as part of comprehensive malaria control and eliminationSalim Abdullah2016PresentationEnglish
P2.4 Reflections on the use of future HIV vaccines as part of an integrated package of preventive measuresWalter Jaoko2016PresentationEnglish
P3 Evolving Global Vaccine MarketsA. BatsonReportEnglish
P3.1 Global vaccine marketAmie Batson2016PresentationEnglish
P4 Preparing for the next Infectious Disease EmergencyHelen Rees, Norman BaylorReportEnglish
P4.1 Preparing for the inevitableDavid Wook2016PresentationEnglish
P4.2 Preparing for the Next Infectious Disease EmergencyLucille Blumberg2016PresentationEnglish
P4.3 Regulatory Preparedness for the Next Infectious Disease EmergencyDelese Mimi Darko2016PresentationEnglish
P5 New Technologies to Support Measles EliminationA. A. Adeyemo2016ReportEnglish
P5.1 What are the measles vaccination coverage gaps?Peter Strebel2016PresentationEnglish
P5.2 The Investment Case for Measles EradicationKimberly Thompson2016PresentationEnglish
P5.3 Measles and Rubella Research AgendaNarendra K Arora2016PresentationEnglish
P5.4 An emerging vaccine delivery technology for measles and rubella eliminationJames Goodson2016PresentationEnglish
P6.1 Universal Influenza Vaccine DevelopmentBarney S. Graham2016PresentationEnglish
P6.2 Vaccine development for Group A StreptococcusAndrew Steer2016PresentationEnglish
P6.3 Schistosomiasis Vaccine UpdatesAnnie Mo2016PresentationEnglish
P6.4 Preferred Product CharacteristicsDavid Kaslow2016PresentationEnglish
W1.0 Introduction: Applying Novel Technologies to Vaccine DevelopmentRino Rappuoli2016PresentationEnglish
W1.1 Structural studies of viral envelope proteins and insights for vaccine designFelix Rey2016PresentationEnglish
W1.2 Epitope-focused vaccine designBill Schief2016PresentationEnglish
W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffoldsNeil King2016PresentationEnglish
W10.1 Monoclonal antibodies for infectious diseasesMartin Friede2016PresentationEnglish
W10.2 Passive vaccination as a global strategy for preventing RSV disease in infantsFilip Dubovsky2016PresentationEnglish
W10.3 Gene-based Delivery of Broadly Neutralizing Antibodies for HIV PreventionWayne Koff2016PresentationEnglish
W10.4 Rabies antibodies for Passive Post-exposure prophylaxisTsepo Tsekoa2016PresentationEnglish
W11 Vaccine HesitancyNarendra Arora2016ReportEnglish
W11.1 Vaccine Hesitancy: what it means and what we need to know in order to tackle itRobb Butler2016PresentationEnglish
W11.2 Vaccine Hesitancy: Determining the scale of the challengeSusan Goldstein2016PresentationEnglish
W11.3 Tailoring Immunization Programmes (TIP): An example of tailoring communication on vaccinations targeting communities in SwedenAnn Lindstrand2016PresentationEnglish
W11.4 Applying TIP to low and middle income settings: a case study from South AfricaNicola Christofides and Janine Simon-Meyer2016PresentationEnglish
W2 Comprehensive assessment of risks and benefits of vaccines: the example of DengueLucky Slamet, Stephen ThomasReportEnglish
W2.2 Public Health Criteria for Dengue Vaccine Risk/Benefit Assessment and Risk ManagementPeter Smith2016PresentationEnglish
W3 Total Systems EffectivenessCarsten Mantel, Darin Zehrung, James Goodson, Jean-Pierre Amorij, Melissa Malhame, Mercy Mvundura, Messeret Shibeshi, Tina Lorenson2016ReportEnglish
W3.1 Introduction: Total Systems EffectivenessTina Lorenson2016PresentationEnglish
W3.2 Total System EffectivenessTina Lorenson2016PresentationEnglish
W3.3 Microarray patch case study: Measles-rubella vaccineDarin Zehrung2016PresentationEnglish
W3.4 Vaccine technology costs and health impact assessment toolMercy Mvundura2016PresentationEnglish
W4.1 Introduction: Antimicrobial Resistance & VaccinesA. A. Adeyemo2016PresentationEnglish
W4.2 WHO Global Action Plan on Antimicrobial ResistanceMartin Friede2016PresentationEnglish
W4.3 The Role of Vaccines in Antimicrobial Resistance StrategiesBruce Gellin2016PresentationEnglish
W4.4 Vaccines to prevent antibiotic-resistant Staphylococcus aureus (MRSA) infectionsOlaf Schneewind2016PresentationEnglish
W4.5 Gonococcal antimicrobial resistance and vaccinesMagnus Unemo2020PresentationEnglish
W4.6 Vaccines for healthcare pathogens: No ESKAPEJordi Rello2016PresentationEnglish
W5 Regulatory Challenges and Constraints When Evaluating Vaccine Clinical TrialsKlaus Cichutek2016ReportEnglish
W5.1 WHO Regulatory Strengthening Update & LMICs Challenges in Vaccine Clinical Trial RegulationWilliam Wekwete2016PresentationEnglish
W5.2 African Vaccine Regulatory Forum (AVAREF): New Vision and Blueprint for Ethics and Regulatory Capacity Strengthening in AfricaDicky Akanmori2016PresentationEnglish
W5.3 Good Participatory Practices for Vaccine Clinical TrialsNelson Michael2016PresentationEnglish
W6 Immunization in the Second Year of LifeRebecca Fields2016ReportEnglish
W6.0 Intro: Establishing a Second-year-of-life (2YL) Healthy Child VisitRudi Eggers2016PresentationEnglish
W6.1 Global landscape analysis and literature review of 2nd year of life immunization platformImran Mirza2016PresentationEnglish
W6.2 Raising the Profile of an 18-month Well-child Visit: the 2YL PlatformElicah Kandinda Kamiji2016PresentationEnglish
W6.3 Protecting Lives in the 2nd Year of Life (2YL) in GhanaAbigail Shefer2016PresentationEnglish
W6.4 Second year of life platform and monitoring systemsJan Grevendonk2016PresentationEnglish
W7.1 The infant microbiome: Relevance to immune responsesMaría Gloria Domínguez-Bello2016PresentationEnglish
W7.2 The Nasal Microbiota: Diversity, Dynamicity, and Vaccine-mediated EffectsJane Deng2016PresentationEnglish
W7.3 Intestinal Microbiota and Enteric Vaccine DesignJames Fleckenstein2016PresentationEnglish
W8 Combination Vaccines: Why and How?A. A. Adeyemo2016ReportEnglish
W8.1 Combination Vaccines: How and Why? Lessons LearnedMichel De Wilde2016PresentationEnglish
W8.2 Combination Vaccines: Potential future statesPeter Dull2016PresentationEnglish
W8.3 Combination Vaccines: Benefits and RisksMelissa Malhame2016PresentationEnglish
W9 Gavi's Vaccine Investment Strategy (VIS)Helen Rees2016ReportEnglish
W9.1 How does Gavi make vaccine investment decisions?Judith Kallenberg2016PresentationEnglish
W9.2 What’s Next for Gavi's Vaccine Investment Strategy: RabiesBernadette Abela-Ridder2016PresentationEnglish
W9.3 Maternal influenza vaccines: How has the VIS process influenced the research agendaSaad Omer2016PresentationEnglish

GVIRF 2014 (English) 

This collection contains materials from GVIRF 2014.

*Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and deliveryAndrew Ford, Angela Hwang, B. Fenton Hall, Joachim Hombach, Nancy Touchette2016Journal articleEnglish
Agenda - GVIRF 2014GVIRF Secretariat2014PresentationEnglish
KN1 Opening Session and KeynoteAnthony Fauci2014ReportEnglish
KN1.1 Vaccine Research and Development: Challenges and OpportunitiesAnthony Fauci2014PresentationEnglish
KN1.2 R&D in the "Decade of Vaccines"B. Fenton Hall2014PresentationEnglish
KN1.3 GVIRF Overview and GoalsJoachim Hombach2014PresentationEnglish
KN1.4 What do we expect from the meeting?José Esparza2014PresentationEnglish
KN2 Research for Universal Health Coverage; Perspective on Vaccines and Poverty ReductionMargaret Chan, Tim EvansReportEnglish
KN2.1 WHO Director-General address to GVIRFMargaret Chan2014PresentationEnglish
KN2.2 Perspectives on Vaccines and Poverty ReductionT. Evans, World Bank2014PresentationEnglish
KN3 Importance of Innovation in Addressing Global Health Gaps in the Developing WorldTrevor MundelReportEnglish
KN3-1 The Importance of Innovation in Addressing Global Health Gaps in the Developing WorldTrevor MundelPresentationEnglish
P1a.1 Status of HIV Vaccine Research & DevelopmentWayne Koff2014PresentationEnglish
P1a.2 Progress towards the development of an HIV vaccine: DiscussionJosé Esparza2014PresentationEnglish
P1b Develop New and Improved Vaccines - TBCharles Mgone, Tom Evans, Uli Fruth2014ReportEnglish
P1b.1 Update on Tuberculosis Vaccines - 2014Tom Evans2014PresentationEnglish
P1b.2 TB Vaccine Development: Challenges & OpportunitiesUli Fruth2014PresentationEnglish
P1c Develop New and Improved Vaccines - MalariaAshley Birkett, Charles Mgone, Peter Smith2014ReportEnglish
P1c.1 Progress towards the development of a malaria vaccineAshley Birkett2014PresentationEnglish
P1c.2 Progress towards the development of a malaria vaccine: discussionPeter Smith2014PresentationEnglish
P2 Regulatory and Public Health Challenges for Vaccines Inducing Modest EfficacyDavid Salisbury2014ReportEnglish
P2.1 Regulatory and public health challengesPeter Smith2014PresentationEnglish
P2.2 Regulatory Considerations for Determining Vaccine EfficacyMarion Gruber2014PresentationEnglish
P3 Developing Next Generation Vaccines: Defining the Improvements Needed and Evaluating Their PotentialK. Neuzil2014ReportEnglish
P3.1 Developing next generation vaccines: IntroductionKathleen Neuzil2014PresentationEnglish
P3.2 Developing Country Vaccine Manufacturers - Access to ImmunizationUmesh Parashar2014PresentationEnglish
P3.3 Developing Next Generation Rotavirus Vaccines: Prospects from the Pipeline to Address Remaining Public Health NeedsMary K. Estes2014PresentationEnglish
P3.4 Evaluation of the Next Generation of Rotavirus VaccinesKathleen Neuzil2014PresentationEnglish
P5 Research to improve monitoring and evaluation of immunization programsJean-Marie Okwo-Bele2014ReportEnglish
P5.1 Immunization Registries in Latin America and the CaribbeanM. Carolina Danovaro-Holliday2014PresentationEnglish
P5.2 Influenza Vaccine Use in the Americas: Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-1Alba Maria Ropero-Alvarez2014PresentationEnglish
P6 Protection of pregnant women, neonates and infants by maternal immunizationHelen Rees2014ReportEnglish
P6.1 Public Health Benefits of Maternal ImmunizationKeith Klugman2014PresentationEnglish
P6.2 Maternal Immunization: which impact on infant immunity?Claire-Anne Siegrist2014PresentationEnglish
P7 Innovative vaccine research: the point of view of industry and biotech companiesMichael Mowatt, Odile LeroyReportEnglish
P7.1 Innovation for vaccines against poverty diseases: the need for new support mechanismsMartin Friede2014PresentationEnglish
P8 General ConclusionB. Fenton Hall, Chris Wilson, Jean-Marie Okwo-Bele2014ReportEnglish
W1 Towards the Development of a Universal Influenza VaccineDavid Spiro2014ReportEnglish
W1.1 Towards the Development of a Universal Influenza VaccineDavid Spiro2014PresentationEnglish
W2 Preferred Product Characteristics (PPC) as a Way to Guide Development of Products of High Public Health UtilityA. A. Adeyemo2014ReportEnglish
W2.1 WHO Preferred Product Characteristics: Bridging Vaccine R&D with Public HealthVasee Moorthy2014PresentationEnglish
W2.2 RSV Vaccine Development for Low and Middle Income Countries: Challenges and ProgressClaudio Lanata2014PresentationEnglish
W2.3 Group A streptococcal vaccines: Challenges and progressFlorian Schödel2014PresentationEnglish
W3.1 Leishmania Vaccine Development: Progress and challenges in the context of other control strategiesFarrokh Modabber2014PresentationEnglish
W3.2 Pre-exposure rabies vaccination (PreP) in children of endemic countriesD. Briggs2014PresentationEnglish
W4 How to Optimize Immunization Coverage? A case study from Measles-Rubella vaccinationA. A. Adeyemo2014ReportEnglish
W4.1 Progress, Challenges, and Lessons Learned in Achieving Measles and Rubella GoalsThomas Cherian2014PresentationEnglish
W4.2 Prioritizing the Research Agenda for Measles and RubellaWilliam Moss2014PresentationEnglish
W5.1 Immunization implementation research priority settingJohn Clemens2014PresentationEnglish
W5.2 Factors influencing community health volunteers in participating in health programs in AfricaFadima YAYA BOCOUM2014PresentationEnglish
W5.3 Strengthening national capacity for evidence-based immunization policy: the case of program costing in HondurasCara Bess Janusz2014PresentationEnglish
W5.4 Building Implementation Research Capacity for Polio EradicationMargaret Gyapong2014PresentationEnglish
W6 Innovation in vaccine delivery and presentation: How can technological advances increase program performance?M. Gottlieb, R. LagosReportEnglish
W6.1 WHO - Next-generation Vaccine Delivery Technology Meeting SummaryDarin Zehrung2014PresentationEnglish
W6.2 Beyond the cold chain… Meningitis A conjugate vaccine in a controlled temperature chain: Experience from BeninOlivier Ronveaux2014PresentationEnglish
W6.3 Case Study: The Uniject Injection SystemDebra Kristensen2014PresentationEnglish
W7 Contributions of Regulatory Science to Vaccine AccessHelen Rees, Norman BaylorReportEnglish
W7.1 Contributions of Regulatory Science to Vaccine AccessNorman W. Baylor2014PresentationEnglish
W7.2 Enhancement in Laboratory Research to Support Innovations in Regulatory Science for the Evaluation of New VaccinesTeeranart Jivapaisarnpong2014PresentationEnglish
W7.3 How can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines?Marion Gruber2014PresentationEnglish
W8 Systems VaccinologyIngileif JonsdottirReportEnglish
W8.1 How can recent technological advances in systems vaccinology accelerate next-generation vaccine development?Ingileif Jonsdottir2014PresentationEnglish
W8.2 Systems VaccinologyBali Pulendran2014PresentationEnglish
W8.3 Application of technological advances to clinical trialsWillem Hanekom2014PresentationEnglish